First Dedicated Leaflet Splitting Device Designed to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement

REHOVOT, ISRAEL / ACCESSWIRE / July 26, 2022 / Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today it received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence the ShortCut™ Pivotal Study, which will assess the safety and effectiveness of the ShortCut™ device. ShortCut™ is the world's first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary obstruction.

The TAVR market, currently estimated at $6 billion, is projected to double over the next five years, with the expansion into low-risk younger patients. However, this growth may be hindered by a fundamental challenge: During TAVR implantation, the leaflets of the pre-existing valve are pushed sideways, in a way which may compromise future coronary access in some patients. This can turn into a life-threatening complication of complete coronary obstruction in a significant number of patients who undergo a second valve implantation when their previous bio-prosthetic valve degenerates. ShortCut™ may be used to split the pre-existing valve leaflets and is designed to prevent coronary obstruction, potentially enhancing the safety of valve-in-valve procedures and expanding the TAVR market.

"Lifetime management for patients with aortic stenosis is increasingly important as we use bio-prosthetic valves more frequently in younger patients, and these valves degenerate over time," said Susheel K. Kodali, MD, Director of Structural Heart & Valve Center at New York Presbyterian/Columbia University Medical Center and US ShortCut™ Study Principal Investigator. "When we then need to implant a second or third valve in a patient, the ShortCut™ device can simply split the leaflets of the previous valve and is designed to facilitate a safe TAVR. Procedures performed to date outside the US demonstrate that ShortCut™ was able to effectively split the leaflets within minutes, allowing for a safe implantation of both self-expandable and balloon-expandable TAVR valves. We are so excited to join our European colleagues and start enrolling patients in the US soon."

ShortCut™ is part of the Pi-Cardia's product portfolio, which includes the Leaflex™ device - a standalone, non-implant-based treatment for patients with aortic stenosis. Leaflex™ performs mechanical scoring of valve calcification and is designed to restore leaflet mobility and improve hemodynamics. Leaflex™ global clinical trials are underway.

"The IDE approval of the ShortCut™ Pivotal Study represents a major milestone, which allows us to now move forward with our clinical plan towards commercialization in the US and Europe," said Erez Golan, Pi-Cardia's Chief Executive Officer. "Given the enthusiasm from US clinicians, we believe ShortCut™ can be the first dedicated leaflet splitting device in the US, coming to market as early as 2024. At the same time, we are making great progress demonstrating the feasibility of our leaflet modification technologies, namely ShortCut™ and Leaflex™, in enabling treatment of bicuspid valves and mitral valves. Each of these future indications represent a significant additional market opportunity for Pi-Cardia".

Pi-Cardia is a global leader in the development of a unique portfolio of non-implant-based solutions for treating heart valves. Pi-Cardia's ShortCut™ device is designed to provide a safe, simple and effective way to split the leaflets of a pre-existing valve prior to TAVR in patients at risk for coronary obstruction. Pi-Cardia's Leaflex™ device mechanically scores valve calcification at multiple locations, with the intention of restoring leaflet flexibility and improving valve hemodynamics. Leaflex™ is designed to be a cost-effective, durable standalone treatment for patients with calcified aortic stenosis. Both leaflet modification technologies could further be used to expand treatment options in bicuspid and mitral valves. The ShortCut™ device and Leaflex™ device are investigational devices, limited by United States law for investigational use.

For more information, please visit: www.pi-cardia.net

Erez Golan CEO erez@pi-cardia.net +972-8-9484800

Eyal Kolka Executive Director eyal@pi-cardia.net

View source version on accesswire.com: https://www.accesswire.com/709640/Pi-Cardia-Receives-FDA-IDE-Approval-for-Pivotal-Study-with-ShortCutTM-Device

SIGA Technologies, maker of the only available monkeypox treatment, is working to ramp up manufacturing for broader global distribution.

A Copenhagen company worked for nearly two decades to develop a vaccine and only six governments bought it. Bavarian Nordic A/S is the world’s sole supplier of a licensed vaccine for monkeypox. The World Health Organization in recent days declared the disease a public health emergency of international concern, the first time the group has issued that designation since the early days of the Covid-19 pandemic.

A few weeks ago, after more than two years of evading COVID-19, I tested positive on a home rapid test.

A vial of insulin cost $25 in 1995, back when Chris Noble was 5 years old and just learning how to manage his Type 1 diabetes with the help of his parents and his doctors. Nearly three decades later, Noble says that same vial of insulin costs more than $300 — a 12-fold increase for something he and millions like him can’t live without. “It’s as essential as water,” Noble said.

Experts share their advice about isolation, masking and more if you're still testing positive late into a COVID-19 infection.

Consistency is most importantBy Hallie LevineWhat time should you take your blood pressure? Here’s the answer to this common question: According to the American Heart Association, the most import...

SARASOTA, Fla - When his blood oxygen dropped to what he described as a critically low level in September, Victor Rohe knew he had "a bad case of covid." But like growing numbers of conservatives here in southwest Florida, Rohe didn't trust the doctors at Sarasota Memorial Hospital to treat him, even though it's part of one of the state's largest and highest ranked medical systems.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Rohe,

One third of Americans have high blood pressure, known as hypertension. "When your blood pressure is too high for too long, it puts you at risk for heart disease, stroke, kidney damage or an aneurysm formation," says Colin A. Craft, MD, physician at Penn Heart and Vascular Center Washington Square. Luckily there are some simple lifestyle changes that can help lower blood pressure. Read on—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1

Gov. Kathy Hochul declared NY's monkeypox outbreak a disaster emergency, citing spikes in cases. It allows authorities to expand vaccine push and more.

Here, a doctor explains what it means to bruise easily, causes, treatments, and when to see a medical professional. Medications and aging are big contributors.

The U.S. has surpassed 5,000 confirmed monkeypox infections, making it the country with the highest number of new cases in the world. University of Michigan Medical School infectious diseases physician Dr. Payal Patel explains steps Americans can take to identify symptoms and reduce the spread.

President Joe Biden has tested positive for Covid-19 again Saturday morning, per a letter from presidential physician Dr. Kevin O’Connor. The results are what is termed a “rebound” Covid-19 positivity. It is “observed in a small percentage of patients treated with Paxlovid,” the doctor said. The President is not experiencing any symptoms, but will isolate at […]

AstraZeneca's Covid-19 antibody drug slashes the risk of new variants emerging, the company said, as Britain faces mounting pressure to follow other Western nations in ordering doses.

'We need vaccines with longer duration and greater breadth of protection,' said Dr. David Kessler, chief science officer for the White House’s COVID-19 response team.

An orthopedic surgeon in Florida caused “hundreds of devastating injuries” while his hospital ignored complaints from patients for years after he started

Experts share their advice for assessing the safety of mysterious new food products.

"This happens with a small minority of folks. I’ve got no symptoms... I’m still at work, and will be back on the road soon," president says Saturday

WASHINGTON—President Biden tested positive for Covid-19 again on Saturday morning in what his physician called a rebound case. Dr. Kevin O’Connor said in a letter made public by the White House that Mr. Biden isn’t experiencing any symptoms and is feeling well. Dr. O’Connor noted a small number of people who take the antiviral medication Paxlovid to treat Covid-19 sometimes test positive again for the virus in what public health officials call “rebound positivity.”

Bella Thorne's toned abs sizzle in a plunging, barely-there halter top in a new Instagram photo. She works out for an hour, and focuses on building muscle.

The US president is not experiencing symptoms, but will isolate again after a fresh positive test.